YuHan YangHaeng Receives Phase 1 Clinical Trial Approval for Chronic Kidney Disease Treatment 'YH34180'... Human Clinical Trials to Begin
YuHan YangHaeng (000100) will begin human trials of YH34180, a treatment candidate for chronic kidney disease (CKD) that it is developing in-house. YuHan YangHaeng announced on the 13th that it has received approval from the Ministry of Food and Drug Safety for its Phase 1 clinical trial plan (IND)

YuHan YangHaeng (000100) will begin human trials of YH34180, a treatment candidate for chronic kidney disease (CKD) that it is developing in-house.
YuHan YangHaeng announced on the 13th that it has received approval from the Ministry of Food and Drug Safety for its Phase 1 clinical trial plan (IND) for YH34180. The approval date was the 6th.
■ Safety and Pharmacokinetics to Be Evaluated First... Involving Healthy Adult Males
In this Phase 1 trial, safety and tolerability will be assessed in healthy adult males following administration. Pharmacokinetic (PK) characteristics, including the drug's absorption, distribution, metabolism, and excretion in the body, as well as pharmacodynamic (PD) characteristics, will also be examined.
■ Oral Small-Molecule New Drug... Targeting Inflammation and Fibrosis Suppression
YH34180 is a small-molecule new drug candidate being developed in oral form. It aims to reduce tissue damage by suppressing inflammation and fibrosis in the kidneys, and to slow the progression of chronic kidney disease and the onset of complications.
■ Kidney Protection Potential Observed in Animal Tests... The Significance of the 'Preclinical Stage'
According to the company, earlier animal tests showed potential for kidney protection. In mice administered the candidate, kidney function-related markers improved, and fibrosis and damage in kidney tissue also decreased. However, these are preclinical results, and the therapeutic effect in humans has not yet been confirmed.
Meanwhile, on the 13th, YuHan YangHaeng's stock closed at 80,300 won, up 500 won (0.63%) from the previous trading day.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



